WO2007076467A3 - Use of anecortave acetate as an adjunct during filtration bleb surgery - Google Patents

Use of anecortave acetate as an adjunct during filtration bleb surgery Download PDF

Info

Publication number
WO2007076467A3
WO2007076467A3 PCT/US2006/062541 US2006062541W WO2007076467A3 WO 2007076467 A3 WO2007076467 A3 WO 2007076467A3 US 2006062541 W US2006062541 W US 2006062541W WO 2007076467 A3 WO2007076467 A3 WO 2007076467A3
Authority
WO
WIPO (PCT)
Prior art keywords
anecortave acetate
during filtration
surgery
filtration bleb
adjunct during
Prior art date
Application number
PCT/US2006/062541
Other languages
French (fr)
Other versions
WO2007076467A2 (en
Inventor
Alan L Robin
Original Assignee
Alcon Inc
Alan L Robin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc, Alan L Robin filed Critical Alcon Inc
Priority to BRPI0620411-2A priority Critical patent/BRPI0620411A2/en
Priority to EP06846780A priority patent/EP1962857A2/en
Priority to AU2006330531A priority patent/AU2006330531A1/en
Priority to JP2008547781A priority patent/JP2009521511A/en
Priority to CA002631838A priority patent/CA2631838A1/en
Publication of WO2007076467A2 publication Critical patent/WO2007076467A2/en
Publication of WO2007076467A3 publication Critical patent/WO2007076467A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Prostheses (AREA)

Abstract

Methods for controlling ocular hypertension by administering anecortave acetate at the site of filtering bleb surgery are disclosed.
PCT/US2006/062541 2005-12-23 2006-12-22 Use of anecortave acetate as an adjunct during filtration bleb surgery WO2007076467A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0620411-2A BRPI0620411A2 (en) 2005-12-23 2006-12-22 use of anecortave acetate as a supplement during hyperfunctioning bag filtration surgery
EP06846780A EP1962857A2 (en) 2005-12-23 2006-12-22 Use of anecortave acetate as an adjunct during filtration bleb surgery
AU2006330531A AU2006330531A1 (en) 2005-12-23 2006-12-22 Use of anecortave acetate as an adjunct during filtration bleb surgery
JP2008547781A JP2009521511A (en) 2005-12-23 2006-12-22 Use of anecoltab acetate as an adjunct during follicular surgery
CA002631838A CA2631838A1 (en) 2005-12-23 2006-12-22 Use of anecortave acetate as an adjunct during filtration bleb surgery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75351105P 2005-12-23 2005-12-23
US60/753,511 2005-12-23

Publications (2)

Publication Number Publication Date
WO2007076467A2 WO2007076467A2 (en) 2007-07-05
WO2007076467A3 true WO2007076467A3 (en) 2007-08-16

Family

ID=38067101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/062541 WO2007076467A2 (en) 2005-12-23 2006-12-22 Use of anecortave acetate as an adjunct during filtration bleb surgery

Country Status (9)

Country Link
EP (1) EP1962857A2 (en)
JP (1) JP2009521511A (en)
KR (1) KR20080078042A (en)
CN (1) CN101346145A (en)
AU (1) AU2006330531A1 (en)
BR (1) BRPI0620411A2 (en)
CA (1) CA2631838A1 (en)
WO (1) WO2007076467A2 (en)
ZA (1) ZA200805052B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080125406A1 (en) * 2005-10-14 2008-05-29 Robin Alan L Method for Treating Primary and Secondary Forms of Glaucoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041867A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Use of steroid compounds to prevent non-cancerous tissue growth
WO1997041852A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Angiostatic compounds
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
WO2005102297A2 (en) * 2004-04-23 2005-11-03 Alcon, Inc. Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041867A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Use of steroid compounds to prevent non-cancerous tissue growth
WO1997041852A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Angiostatic compounds
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
WO2005102297A2 (en) * 2004-04-23 2005-11-03 Alcon, Inc. Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHAUNAK SUNIL ET AL: "Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation", NATURE BIOTECHNOLOGY, vol. 22, no. 8, August 2004 (2004-08-01), pages 977 - 984, XP002436146, ISSN: 1087-0156 *
WONG JAMIE ET AL: "Modulation of human fibroblast activity by selected angiogenesis inhibitors", EXPERIMENTAL EYE RESEARCH, vol. 58, no. 4, 1994, pages 439 - 451, XP002436145, ISSN: 0014-4835 *

Also Published As

Publication number Publication date
AU2006330531A1 (en) 2007-07-05
EP1962857A2 (en) 2008-09-03
CA2631838A1 (en) 2007-07-05
CN101346145A (en) 2009-01-14
JP2009521511A (en) 2009-06-04
WO2007076467A2 (en) 2007-07-05
BRPI0620411A2 (en) 2011-11-08
KR20080078042A (en) 2008-08-26
ZA200805052B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
EP1638508A4 (en) Shunt for the treatment of glaucoma
WO2005068421A8 (en) Prostaglandin nitrooxyderivatives
WO2007020213A3 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
IS7215A (en) Methods for the treatment of ocular diseases of the eye
AU2003297684A1 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2006091567A3 (en) Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2004075864A3 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2008060767A3 (en) Macrocyclic benzofused pyrimidine derivatives
EP1814535A4 (en) Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
IS7822A (en) Eye Compositions for the Treatment of Ocular Hypertension
AU2003223224A8 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
EP1664011A4 (en) Ophthalmic compositions for treating ocular hypertension
NZ597866A (en) Therapeutic lactams
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
CL2007003836A1 (en) USE OF COMPOUNDS DERIVED FROM ISOSORBIDE IN THE PREVENTION AND / OR TREATMENT OF OPHTHALMOLOGICAL DISEASES MEDIATED BY OCULAR HYPERTENSION, SUCH AS GLAUCOMA.
WO2004108673A3 (en) Inhibitors of papilloma virus
EP1581503A4 (en) Ophthalmic compositions for treating ocular hypertension
WO2004093805A3 (en) Selective spirocyclic glucocorticoid receptor modulators
EP1771170A4 (en) Ophthalmic compositions for treating ocular hypertension
WO2006007227A3 (en) Abnormal cannabidiols for lowering intraocular pressure
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
AU2003241398A1 (en) Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680048926.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2631838

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006330531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/007884

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006846780

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008547781

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006330531

Country of ref document: AU

Date of ref document: 20061222

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087016572

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0620411

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080623